TELA Bio, Inc. (TELA) Q1 2026 Earnings Call Transcript

TELA Bio, Inc. (TELA) Q1 2026 Earnings Call Transcript

Seeking Alpha • May 13, 2026

TELA Bio Reports First Quarter 2026 Financial Results

MALVERN, Pa., May 12, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA Bio”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results for the first quarter ended March 31, 2026.

GlobeNewsWire • May 12, 2026

TELA Bio, Inc. (TELA) Reports Q1 Loss, Beats Revenue Estimates

TELA Bio, Inc. (TELA) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to a loss of $0.25 per share a year ago.

Zacks Investment Research • May 12, 2026

TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MALVERN, Pa., May 07, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of restricted stock units covering 89,250 shares of its common stock to 12 newly-hired employees, with a grant date of May 5, 2026 (the "Grant Date").

GlobeNewsWire • May 7, 2026

TELA Bio Announces Strategic Board Refreshment with Four Highly Experienced Commerical Leaders to Accelerate Growth and Drive Path to Profitability; The Company Also Reports Preliminary First Quarter 2026 Revenues

MALVERN, Pa., April 30, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA Bio”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced a comprehensive board refreshment plan designed to support the Company's next phase of commercial growth and operational excellence.

GlobeNewsWire • Apr 30, 2026

TELA Bio to Announce First Quarter 2026 Financial Results

MALVERN, Pa., April 21, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will report first quarter 2026 financial results on Tuesday, May 12, 2026. TELA Bio's management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update.

GlobeNewsWire • Apr 21, 2026

TELA Bio Analysts Cut Their Forecasts After Q4 Results

TELA Bio, Inc. (NASDAQ: TELA) reported mixed results for the fourth quarter on Tuesday.

Benzinga • Mar 25, 2026

TELA Bio, Inc. (TELA) Q4 2025 Earnings Call Transcript

TELA Bio, Inc. (TELA) Q4 2025 Earnings Call Transcript

Seeking Alpha • Mar 24, 2026

TELA Bio Reports Fourth Quarter and Full Year 2025 Financial Results

MALVERN, Pa., March 24, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results for the fourth quarter and full year ended December 31, 2025.

GlobeNewsWire • Mar 24, 2026

TELA Bio, Inc. (TELA) Reports Q4 Loss, Lags Revenue Estimates

TELA Bio, Inc. (TELA) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to a loss of $0.23 per share a year ago.

Zacks Investment Research • Mar 24, 2026